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Symptoms characteristic of epilepsy have been recognised relatively well at the 
very beginning of medicine. Despite that fact, mechanisms underlying the disease 
still remain unknown. The brain injury has been commonly considered as one of the 
most powerful triggers for epileptogenesis. It appeared, therefore, obvious that the 
application of neuroprotective drugs minimising effects of injury would also protect 
the brain from epileptogenesis. However, a question has been raised that the neu-
roprotective treatment might not always be beneficial to the injured brain, since it 
would also promote the survival of neurons of functional features permanently 
modified under pathological condition. Therefore, the neuronal survivors them-
selves might constitute the source of initial seizures or show an increased suscepti-
bility to seizuregenic stimuli. Indeed, it has already been demonstrated that long-
term effects of neuroprotective drugs might not always have a positive influence 
on further susceptibility of the injured brain to seizures. On the contrary, application 
of neuroprotectants during the course of epileptic seizures may instead result in 
smaller structural and functional impairments. Finally, effective stimulation of en-
dogenous neuroprotective potential existing in the injured brain also became the 
subject of experimental verification. Apparently, physical exercise is a promising 
example of this therapeutic approach. 
 
 
 
 
Animal models of epilepsy; Neuroprotection; Brain injury 
REVIEW 
IJNN 2007 ; 4 (1): 41-51  
© GCNN Limited. All rights reserved 
Key Words 
For many years, epilepsy has been a serious 
clinical problem. According to a WHO esti-
mate, about 50 million people suffer from this 
disease worldwide. In recent years, there has 
been a rapid progress in its diagnosis and ther-
apy due to the engagement of experts from 
various fields of pharmacology, surgery, neurol-
ogy and neurobiology. New antiepileptic 
drugs, such as felbamate, gabapentin, lamo-
trignine, vigabatrin and many others1 were in-
troduced thanks to the co-operation of inter-
disciplinary teams. Unfortunately, exact causes 
and mechanisms of epileptic discharges are 
still unknown, which greatly hinders attempts to 
efficiently counteract the development of this 
disease. 
Animal models of epilepsy 
 
Studies on epileptogenesis or new antiepileptic 
drugs require the use of animal models of epi-
leptic seizures. In the search for an ideal model 
of epilepsy, more than 50 different methods of 
seizure induction have already been de-
scribed. An ideal model should present a pic-
ture possibly the most closely resembling clini-
cal symptoms in humans2. Seizures should be 
accompanied by the changes in electroen-
cephalographic activity of the brain. If a 
model fulfils these criteria, it can be used for 
studies of the mechanisms underlying epilepto-
genesis, and for the development of new 
treatment strategies.  
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The pilocarpine model of temporal lobe epi-
lepsy has been in use for about 25 years. This 
model was created by Waldemar Turski, a Pol-
ish scientist, who was the first to observe that 
the administration of the cholinergic agonist, 
pilocarpine, to rats induced limbic seizures 
manifested by an array of behavioural symp-
toms and characteristic changes in EEG. After 
acute phase of seizures, isolated seizures in ani-
mals which survived status epilepticus could 
even be observed for several years3. Histologi-
cal analysis of brains of pilocarpine-treated 
animals demonstrated a number of pathologi-
cal changes in the olfactory bulb, amygdala, 
thalamus, hippocampus and neocortex3,4. An 
important weakness of the pilocarpine model is 
the high mortality of animals which can, how-
ever, be prevented by lowering pilocarpine 
doses and its combination with lithium chlo-
ride5. 
 
Treatment with the glutamatergic agonist, kai-
nic acid, is another method used to trigger epi-
leptic seizures. Such treatment elicits several 
characteristic behavioural and electroen-
cephalographic changes. Histological analysis 
shows lesions in brain regions similar to those 
caused by pilocarpine, but the changes are 
less conspicuous6. 
 
Seizures can be provoked also by strychnine, 
pentetrazole, excitatory amino acids and 
many other substances5. 
 
Recently, a research team led by Turski7 pro-
posed a new model of epilepsy. Methomyl was 
used as a seizurogenic substance. It is a car-
bamate commonly used as an insecticide 
which can reversibly inhibit choline esterase 
activity. Methomyl in combination with lithium 
evokes limbic seizures followed by neurode-
generative changes and characteristic EEG 
alterations, but does not cause high mortality7. 
For this reason, this model can be an alterna-
tive to the models of epilepsy used so far. 
 
Beside treatment with various substances, sei-
zures can be provoked by a single electrical 
stimulation via ear clip electrodes8 or by re-
peated subthreshold stimulation (kindling). The 
latter method requires implantation of elec-
trodes which per se injures the brain and may 
be epileptogenic. 
 
The models of epileptic seizures presented above 
are most frequently used in experimental studies. 
Besides, there are a number of other models of 
epilepsy, e.g. models utilising visual or auditory 
stimulation, or genetic manipulation2. 
 
Post-traumatic epilepsy 
Brain injury following ischemia or trauma is one 
of the possible causes of epileptic seizures. De-
velopmental malformations in the brain lead-
ing to permanent changes in its structure may 
also underlie epileptogenesis9. 
 
Clinical studies demonstrated that 50% of pa-
tients who suffered a penetrating brain injury 
developed epilepsy10-13. The risk of post-
traumatic epilepsy increased with lesion sever-
ity, nevertheless, epilepsy could develop even 
in patients experiencing very small lesions14. 
Clinical studies, however, do not always guar-
antee effective exploration of effect of the 
injury on epileptogenesis since etiology of this 
disease in humans is usually not completely 
clear. Therefore, animal models of epilepsy or 
mechanical brain injury are used to elucidate 
this problem in more detail15-17. In these models, 
an effort is made to unambiguously define all 
parameters of seizures. Usually these studies are 
carried out on adult animals, therefore, it is diffi-
cult to speculate on that basis what effects 
such injury would elicit in the immature brain.  
 
On the other hand, clinical studies report that 
children and teenagers are the groups in 
greatest danger of head injuries. The resulting 
brain injuries are the most frequent cause of 
neurological disorders (including post-
traumatic epilepsy) in children17,18. 
 
For these reasons, recent studies of epilepto-
genesis focus on the search for means how to 
prevent development of epilepsy of different 
etiologies, particularly post-traumatic epilepsy 
in children and adults. 
 
3. Experimental models of epilepsy 
3.1. Pilocarpine model of epilepsy 
 
In order to elucidate how mechanical injury 
influences brain susceptibility to epileptic sei-
zures, a well-known model of penetrating injury 
of the brain hemisphere was used. In this 
model, the integrity of cranium and meninges 
was broken showing, therefore, a good anal-
ogy to sudden and traffic accidents19-22. Two 
animal groups were subjected to this kind of 
injury on postnatal days 6 or 30 (P6 and P30, 
respectively, Fig. 1 shows a general scheme of 
the experiment):  
 Fig. 1.  
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When the animals became 60 days old (P60s), 
they received pilocarpine injections to induce 
status epilepticus (SE)23. Thereafter, all behav-
ioural symptoms were assessed. It was proven 
that susceptibility to the seizures depended on 
the developmental stage at which the me-
chanical injury was performed.  
 
In rats injured on P6, the course of seizures 
evoked on P60 did not differ from that ob-
served in controls. On the contrary, brain injury 
on P30 severely increased susceptibility to sei-
zures. Moreover, the proportion of survivors on 
the seventh day of the experiment in animals 
injured on P6, was higher than in the control 
group. On the contrary, mortality of animals 
injured on P30 was extremely high, and 
reached 97%23. The evidence that injury on P6 
did not increase the susceptibility to epileptic 
seizures evoked in mature animals does not 
agree with clinical data showing that paediat-
ric insults are most epileptogenic12,24. 
 
Probably, diverse predisposition to seizures in 
animals injured on P6 or P30 is partially a result 
of different, age-dependent structure of the 
injury-induced glial scar. This is in agreement 
with pioneering research of Penfield25, who first 
indicated the relation between astrogliosis and 
epilepsy. Maxwell and co-workers26 proved 
that in animals injured in the first postnatal 
week, glial scar remains dispersed and permis-
sive to neuronal regeneration process27. Follow-
ing the similar brain injury made in one-month-
old animals, the glial scar has compact struc-
ture constituting a physical barrier for growing 
axons28 making the restoration of damaged 
neural connections impossible. Apart from this, 
the scar is also a potent biochemical barrier 
producing axonal growth inhibitors29. All the 
injury-induced structural and biochemical 
changes could be responsible for the signifi-
cant differences in susceptibility to seizures be-
tween the two age groups. It is worth remem-
bering that astrocytes have their own calcium-
dependent mechanisms of excitation, with 
surface receptors and ion channels, like in neu-
ronal cells. For these reason, actrocytes can be 
considered as a primary source of epileptic 
activity30. It may depend on the changes in 
proportion and functional interfaces between 
astrocytes and neurons, especially after injury-
induced glial proliferation and modification of 
extracellular environment.  
 
Moreover, many cells within the region of injury 
undergo apoptotic or necrotic changes31. 
However, if they can survive, they may also be 
able to create additional pathological con-
nections underlying increased susceptibility to 
spontaneous epileptic discharges or to seizure-
genic stimuli and, therefore, facilitating occur-
rence of status epilepticus.   
 
3.2. Kainic acid model of epilepsy 
 
In clinical settings, we are not sure enough 
which neurotransmitter systems are involved in 
epileptogenesis and/or seizure processes. Ani-
mal models of seizures improve the situation by 
application of appropriate seizuregenic sub-
stances that can activate selected neuronal 
populations. Nevertheless, definition of specific 
neural subsystems responsible for changes in 
susceptibility to seizures can be much less ef-
fective. It is always necessary to keep in mind 
that the changes are observed in a given ani-
mal model following application of a specific 
seizure-generating substance that activates 
selected functional subsystems. Consequently, 
all the above-presented phenomena can 
rather be considered as characteristic of the 
pilocarpine model of epilepsy23. In order to re-
solve, if the activation of another neurotrans-
mitter systems can produce similar effects, an-
other model of epileptic seizures using kainic 
acid was applied in the same experimental 
paradigm32. Since kainic acid is a glutamater-
gic agonist, its dosage was calculated on the 
basis of data from experiments by other au-
thors, to produce similar histopathogical and 
behavioural changes6,33. Contrary to previously 
described results obtained using pilocarpine 
model of epilepsy23, adult rats with brains in-
jured on P30 showed no change in their sus-
ceptibility to kainic acid-induced seizures. Fur-
thermore, brain injury performed on P6 led to 
significant amelioration in the course of seizures 
in the same experimental conditions. The results 
indicate that the brain injury may have differ-
ent influence on long-term susceptibility to sei-
zures when agents used to evoke the seizures 
activate functionally different neuronal subsys-
tems. Changes in susceptibility to seizures fol-
lowing brain injuries performed at different de-
velopmental stages may also present different 
profiles depending on the experimental model, 
i.e. when pilocarpine or kainic acid were cho-
sen as seizuregenic agents23,32. Each of the two 
models of epilepsy might display different as-
pects of the same age-dependent process 
triggered by the brain injury. These facts show 
clearly that no general and unequivocal con-
clusion concerning mechanisms of epipleto-
genesis can be obtained on the basis of ex-
periments using a single experimental model of 
epilepsy since the process appears to depend 
on multiple functional subsystems.  
 
Potential for use of CsA and FK506 in antiepi-
leptic therapy 
 
Since, as mentioned earlier, each brain injury may 
have irreversible consequences, factors that 
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could prevent development of post-traumatic 
changes have been tested for many years. Com-
pounds that can minimise the effects of brain 
injury by increasing the ability of nervous cells to 
survive under pathological conditions are defined 
as neuroprotective factors. 
 
In experimental studies, such substances can 
either be administered systemically or the or-
ganism itself can be stimulated to produce 
neuroprotective factors. If such factors are 
considered to be used in clinical practice, they 
should be thoroughly examined in preclinical 
studies. Unfortunately, only a few of them fulfil 
requirements for being used to treat humans.  
 
Immunosuppressive action of CsA and FK506 
 
CsA was first described as neuroprotective 
compound based on experimental studies by 
Shiga et al34. Until then, it had been exclusively 
used as an immunosuppressant. CsA is a lipo-
philic undecapeptide isolated from the fungus 
Tolrypocladium infantum Gams in 197635. It has 
a wide-ranging biological action as a fungi-
cide, and an antiparasitic or anti-inflammatory 
agent. Finally, it is used as an immunosuppres-
sant in transplantology36,37, in autoimmune dis-
eases of the skin38 and of the nervous system39 
and in rheumatism40. 
  
FK506 (Tacrolimus, commercial name Prograf), 
isolated from the fungus Streptomyces tsu-
kubensis in 1984, shows similar actions to CsA41. 
It has been successfully used for the prevention 
of liver and heart graft rejection. When this 
drug is used, it is not necessary to administer so 
high doses of corticosteroids as in posttrans-
plantational therapy with CsA42. 
 
The main therapeutic effect of the two com-
pounds consists in the inhibition of lymphocyte 
T activation43,44. When CsA or FK506 have en-
tered the cell, they bind to cyclophilins (CyPs) 
or FK binding proteins (FKBPs), known also as 
immunophilins45. CyPs or FKBPs complexes are 
able to inhibit the activity of calcineurin, which 
is an enzymatic protein with phosphatase ac-
tivity. Because of its ability to cleave phos-
phate groups, it is engaged in many metabolic 
reactions critical for cell function. 
 
Calcineurin is involved in the regulation of ion 
channel activity46, and controls neurotransmitter 
release47 and nitric oxide synthase activity48, 
moreover, it is engaged in signal transmission in 
the cell49. 
 
The activated calcineurin dephosphorylates 
nuclear factor of activated T cells (NFAT), 
among other molecules, which leads to con-
formational changes exposing site of NFAT 
transport to the nucleus. NFAT has relatively low 
affinity for DNA and interacts with other tran-
scription factors to activate such promoters as 
IL-2,IL-3, GM-CSM, TNF and Fas ligand, which 
initiate T cell activation50. Therefore, if cal-
cineurin is inhibited, IL-2 cannot be activated, 
which disables full activation of T cells51,52. 
These phenomena are the basis of well-
established immunosuppressant action of CsA 
and FK506. 
 
By inhibiting calcineurin activity, CsA and FK506 
affect also the activity of another transcription 
factor CREB (cAMP response element-binding), 
which amplifies their immunosuppressant activ-
ity53,54. 
 
4.2. Neuroprotective action of immunosuppres-
sive compounds 
 
Many years of the studies of neuroprotective 
action of the above-mentioned immunosup-
pressive compounds paved the way for their 
use in different models of brain (traumatic 
brain injury, global and partial ischemia) or pe-
ripheral nervous system injury. 
 
4.2.1. Neuroprotectine action of cyclosporine 
 
The experiments presented below illustrate the 
action of neuroprotective compounds in the 
selected models of brain injury that most 
closely simulate clinical situations. 
 
CsA (10 mg/kg) administration for seven days 
before ischemia induction significantly re-
duced infarct area. Most probably, it was at-
tributable to the activation of TrKa receptor of 
brain-derived neurotrophic factor (BDNF)55. 
CsA injection significantly increased the level of 
phosphorylated CREB (pCREB), which was ear-
lier observed in hippocampal cells resistant to 
hypoxia-induced damage56,57. CsA at 20 mg/
kg decreased number of destroyed striatal 
dopaminergic neurons in an animal model of 
Parkinson’s disease58. CsA (10 mg/kg) adminis-
tered after hypoxia induced by middle carotid 
artery occlusion (MCAO) significantly reduced 
degeneration area59. 
 
In the peripheral nervous system, CsA (2.5 mg/
kg) administered 72 h before injury and an hour 
afterwards decreased demyelisation and num-
ber of vanishing nervous cells and supported 
recovery of motor functions60. It also lowered 
proliferative activity of astrocytes in the injured 
brain (our unpublished studies). 
 
4.2.2. Neuroprotective action of FK506 
 
FK506 (1 mg/kg) administered after sciatic 
nerve section facilitated regeneration of pe-
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ripheral axons by increasing the level of growth 
factors61. Likewise, a single injection of FK506 (3 
mg/kg) 30 min before traumatic brain injury 
significantly diminished number of damaged 
neurons62. It reduced the area of hypoxia-
induced damage in MCAO model even by 
58% but only when it was administered in the 
dose range from 1 mg/kg to 10 mg/kg and not 
later than 2h after hypoxia63,64. The latest ex-
periments have indicated that the mechanism 
of neuroprotective action of immunosuppres-
sive drugs can depend on non-neuronal com-
ponents of the nervous tissue. Specifically, it 
was noted that post-injury FK506 treatment 
modulated activity of astrocytes and microglia 
which was accompanied by lowering of astro-
cytic IL-1b mRNA and TNFa mRNA levels65. 
Moreover, astrocytic proliferation was reduced 
in the brains of animals that were treated with 
FK506 after mechanical brain injury (our unpub-
lished results). It is probable that a combined 
treatment with FK506 and tissue plasminogen 
factor can be helpful in clinical treatment of 
brain ischemia66. 
 
A few examples of studies of neuroprotective 
action of CsA and FK506, presented above, 
provide evidence that these two compounds 
show neuroprotective activity in adult animals 
only when they are applied at appropriate 
time after injury. The time elapsing between 
the injury and treatment should be short 
enough to allow for onset of neuroprotective 
agent’s action before irreversible changes ac-
tually occur (therapeutic time window67). Obvi-
ously, the neuroprotective drugs should also be 
administered at appropriate doses that assure 
the most beneficial therapeutic effects with 
tolerable negative side effects for the organ-
ism. 
 
Effect of neuroprotective compounds on epi-
lepsy progression 
 
5.1. Posttraumatic neuroprotection 
 
Experimental studies repeatedly demonstrated 
neuroprotective action of CsA and FK506. Ad-
ministration of these compounds after brain 
injury, which minimizes injury consequences, i.e. 
decreases necrosis area, reduces number of 
vanishing neurons, inhibits development of glial 
scars, could be the basis for more advanced 
clinical therapy.  
 
Taking into consideration epileptogenicity of 
brain injury, known from clinical practice13, and 
varying post-injury vulnerability to epileptic sei-
zures in animals23, we decided to check 
whether the administration of neuroprotective 
compounds after brain injury would change 
predisposition to manifestation of seizure activ-
ity. To attain this goal, animals, whose brains 
were injured at different periods of postnatal 
life (P6 or P30), were administered cyclosporine 
A or FK506. Subsequently, when the animals 
were 60 days old, they were administered pilo-
carpine to induce seizures. We observed that 
pilocarpine-evoked seizure activity in 60-day-
old animals with brains injured on P6 adminis-
tered FK506 did not significantly differ from 
those which did not receive any neuroprotec-
tant after injury. However, animals injured on P6 
but treated with CsA after injury, showed ag-
gravated seizures elicited on postnatal day 60 
and mortality in this group was extremely high. 
On the other hand, post-injury FK506 treatment 
following brain injury performed on P30 did not 
significantly affect seizures evoked in adult-
hood but survival rate was increased. CsA 
treatment after injury in this age group pro-
longed seizure activity but markedly increased 
survival time after experimentally induced epi-
lepsy68. 
 
These results did not provide full confirmation of 
the initial hypothesis assuming lighter seizures 
after treatment with neuroprotectants, but 
they proved that CsA and FK506 induced per-
sistent changes in the damaged nervous tissue 
thereby changing its functional properties. It 
was manifested by the increased susceptibility 
to seizures, particularly after CsA treatment, 
whereas FK506 injection did not cause such 
changes but significantly prolonged survival 
after acute phase of seizures68. 
 
The question arises, therefore, whether final 
effects of neuroprotective intervention, evalu-
ated only quantitatively (larger number of neu-
rons protected from degeneration) is always 
functionally beneficial, since this is functional 
but not anatomical (structural) improvement 
which would justify implementation of neuro-
protective strategy. Results of experimental 
studies usually are considered to be quite satis-
factory if the number of surviving neurons in 
some damaged areas of the brain is increased 
or necrotic area is reduced. However, the stud-
ies presented above showed that the post-
injury administration of compounds with well-
defined neuroprotective action could have 
increased brain susceptibility to seizures. There-
fore, it is possible that neuroprotection, whose 
efficacy is conspicuous at quantitative level 
and demonstrable by histological studies, not 
always leads to functional improvement of 
damaged brain, but, surprisingly, can even 
cause functional deterioration, since charac-
teristics of ‘rescued’ neurons had been perma-
nently modified by pathological posttraumatic 
conditions.  
 
It should be remembered that cyclosporin A 
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and tacrolimus have non-polar molecules and 
thus they are not soluble in water. In post-
transplational therapy, these drugs are admin-
istered in appropriate pharmaceutical formula-
tions to achieve therapeutic effect69. Sub-
stance in which an active substance is dis-
solved or suspended is called vehicle. In this 
case, a mixture of NaCl, Cremofor and ethyl 
alcohol was used as vehicle. Cremofor 
(modified castor oil) is the main component of 
the vehicle. Cremofor is obtained from Ricinus 
communis seeds and is characterised by very 
high viscosity and contains glycerides of rici-
noleic acid, stearates and dihydroxystearic 
acid70. Such vehicle composition increases sta-
bility of the drug stored in the form of solution. 
Moreover, Cremofor is a surface-active agent 
increasing solubility of the active compounds71. 
The vehicle contains also 0.25% ethanol in 0.9% 
NaCl. It improves drug solubility and uptake72. 
  
It seems obvious that in order to be able to 
unequivocally assess CsA and FK506 potentials 
as the agents preventing seizure development 
after brain injury, it is crucial to test biological 
effects of vehicle in the same experimental 
design. 
 
5.2. Effect of CsA and FK506 on acute phase of 
epilepsy 
 
Clinical studies and animal models of epilepsy 
indicate that even a short episode of epileptic 
convulsions can produce local or remote neu-
rodegenerative changes5. Neuronal death in 
vulnerable brain structures in rats can be ob-
served already after epileptic discharges (in 
EEG recording) of 4-16 min duration73,74. Seizure 
activity probably leads to the activation of 
postsynaptic NMDA receptors due to excessive 
glutamate release from presynaptic structures, 
and excessive calcium influx inside neurons, 
which can elicit numerous transformations, 
even cell death. 
 
Hence, minimisation of the changes triggered 
by spreading seizures is the important goal of 
clinical neurology. Since apoptosis in one of 
processes occurring in epileptogenic focus 
and remote areas, treatment with such neuro-
protective compounds as CsA and FK506 
could minimise post-epileptic tissue deteriora-
tion. 
 
In order to test this hypothesis, CsA or FK506 
were administered to animals with pilocarpine-
induced seizures when seizures were of inter-
mediate intensity according to Racine’s 
scale23,68. Subsequently, the animals were ob-
served for seizure progression. These experi-
ments demonstrated that FK-506-treated ani-
mals showed lighter seizures than control ani-
mals and survived significantly longer. CsA ad-
ministration also alleviated seizure intensity and 
prolonged survival time after seizure initiation75. 
Therefore, it can be assumed that each of the 
used compounds had a beneficial effect on 
the course of experimentally induced seizures, 
making them milder. It seems that the com-
pounds under discussion can be efficient only 
when they are administered in the acute 
phase of seizures. Thus, they can presumably 
be considered to be primary neuroprotectants, 
since they counteract initial phenomena lead-
ing to neuronal death consequent to the 
spread of excitatory wave triggered probably 
by activation of voltage-gated Na+ and Ca2+ 
channels or glutamate receptors76. 
 
The above-described experiment does not 
unequivocally answer the question whether 
the studied compounds acted as primary neu-
roprotectants or by inhibiting the cascade 
leading to cell death, thereby contributing to 
secondary neuroprotection. The studies were 
carried out only for the first six hours after sei-
zure initiation, thus, they should be linked with 
phenomena occurring in the early phase of 
epileptic activity, like excessive stimulation or 
primary neurodegenerative changes77. Since 
the used compounds have neuroprotective 
activity, it can be assumed that they can save 
neurons in epileptogenic focus or its vicinity 
from death or degeneration78. However, char-
acteristics of those cells can be permanently 
changed, which may constitute a source of 
epileptic activity or susceptibility to seizures in 
the future. This hypothesis can be verified by 
further experiments with longer survival time 
after seizure initiation. If we envisage using 
compounds of similar type (calcineurin inhibi-
tors) in clinical practice, we will also have to 
check whether they do not elicit undesirable 
effects in combination with currently used an-
tiepileptic drugs. 
 
6. Alternative forms of neuroprotective inter-
vention: endogenous neuroprotection 
 
It should be remembered that numerous com-
plex processes occurring in damaged nervous 
tissue (degeneration, glial activity, regenera-
tion) activate different tissue factors. Some of 
them can afford neuronal protection, particu-
larly under pathological conditions. The pres-
ence of these factors or their absence can be 
decisive for death or survival of neurons at risk. 
Since these factors are produced by the nerv-
ous tissue itself, they are endogenous agents, 
therefore, their positive effect can be termed 
endogenous neuroprotection. It was discov-
ered that moderate physical exercise can be 
one of situations inducing release of such en-
dogenous neuroprotective factors. 
47 
How can neuroprotective drugs (FK506 and CSA) affect epileptogenesis and  
susceptibility to status epilepticus in the normal and pathological brain? 
As well as improving physical fitness in humans, 
moderate physical exercise improves psychical 
well-being, elevates mood, alleviates depres-
sion and decreases aggression79. Motor training 
elicits also a number of changes in the nervous 
system, alters the levels of neurotransmitters: 
glutamate, aspartate and serine80, and modi-
fies expression of endogenous growth fac-
tors81,82. Furthermore, exercise promotes brain 
vascularisation83-86.  
 
Many experiments investigating electrical ac-
tivity of the brain have proven that exercise 
can terminate non-physiological discharges 
but they return when training is over87. 
 
Setkowicz and Mazur88 investigated whether 
regular long-term exercise of moderate inten-
sity (45-day training on treadmill and swim-
ming) changed susceptibility of adult rats to 
pilocarpine-induced epilepsy. The obtained 
results unequivocally confirmed that moderate 
exercise elicited a significant positive effect, 
since the course of experimentally induced 
seizures was milder in trained animals than in 
controls (Fig. 2).  
Fig. 2. Changes in the intensity of behavioural symptoms 
evoked by pilocarpine injections in trained and control, non-
trained rats (thick and thin curves, respectively). Rating 
scores of the symptoms were summarised separately for 
each of six consecutive one-hour periods (H1-6) following 
pilocarpine injection. Triangles and circles represent the 
trained and control groups, respectively. Each decimal in-
dex shows statistical significance of difference between the 
two groups (Mann-Whitney test). 
 
The neuroprotective effect of running may  
possibly be attributed to the formation of 
greater number of synapses89, which results 
from the increased BDNF mRNA and BDNF ex-
pression in the hippocampus90. BDNF was ob-
served to inhibit excitotoxic changes in neu-
ronal cultures91, and to reduce ischemia conse-
quences in vivo92. Therefore, it is believed that 
elevation of its level during exercise is accom-
panied by neuroprotective effect93. It is also 
possible that exercise-induced rise in BDNF 
level triggers regulatory processes leading to 
the increase in neuropeptide Y level, which 
suppresses epileptic discharges94. In addition, 
exercise enhances neurite growth factor (NGF) 
level. NGF can protect cells against hypogly-
cemia and excitotoxicity by reducing intracel-
lular calcium excess95. BDNF and NGF show 
also ability to boost activity of free radical 
scavengers96, making the organism less endan-
gered by their harmful effects. It is, thus, possi-
ble that, owning to the above-described prop-
erties, the NGF released during exercise abro-
gates pilocarpine-induced epileptic changes.  
 
In other models of seizures, e.g. in the kindled 
seizures, trained animals were observed to re-
quire greater number of stimulations in order to 
elicit stage 5 seizures according to Racine’s 
scale than non-trained animals97, which cor-
roborates positive effect of exercise. 
 
Opposite effects were described by Ramsden 
et al.98, who noted aggravation of neuronal 
damage after kainic acid-induced seizures in 
females subjected to physical exercise. 
 
Advantages of endogenous over exogenous 
neuroprotection 
 
Based on the above-described facts, it can be 
inferred that the application of substances 
commonly known to be neuroprotective after 
brain injury not necessarily has to have positive 
functional effects. Therefore, despite histologi-
cal demonstration of distinctly increased neu-
ronal survival in a damage area, this positive 
change may not be beneficial in terms of fu-
ture susceptibility to epileptic attacks. The stud-
ies discussed in this review did not investigate 
such changes, so further experiments are nec-
essary to clarify this issue. It is also required to 
examine the effects of vehicle components on 
development of epilepsy. Moreover, it is impor-
tant to distinguish to what extent the neuropro-
tectant and the injury itself contribute to the 
observed changes. Therefore, CsA and FK506 
effects should be examined also in the unin-
jured brain. Obviously, it is essential to take ac-
count of developmental changes occurring in 
the brain in the period when neuroprotective 
drugs are administered. Surprisingly, despite 
lack of these data, the analysed drugs have 
been used in posttransplational therapy in chil-
dren for many years. 
 
The administration of neuroprotective com-
pounds in acute phase of seizures in animals 
brought positive effects and lowered seizure 
activity75. However, long-term consequences 
of their use are uncertain, although their long-
lasting use in post-transplational therapy is 
known to be associated with the risk of differ-
ent side effects99,100. 
 
Luckily, the stimulation of endogenous neuro-
protection, like through exercise, seems propi-
48 
tious. Endogenous neuroprotection has no side 
effects accompanying the activation of vari-
ous intracellular factors promoting neuronal 
survival. Furthermore, experiments refuted long-
standing conviction that epileptic patients 
should avoid exercise. It may be expected that 
regular exercise of moderate intensity can 
counteract the increased susceptibility to sei-
zures after injury. This hypothesis unquestionably 
requires experimental verification. Contemplat-
ing clinical use of neuroprotection free of side 
effects or invasive therapies, namely, endoge-
nous neuroprotection, one should check 
whether the stimulation of intracellular repair 
systems is efficient in any experimental model 
of epilepsy. While attempting to apprise en-
dogenous treatment strategies, one should 
take notice of the fact that all experiments pre-
sented here were carried out on males. Actu-
ally, epilepsy incidence in women and men is 
comparable, but experimental data indicate 
that seizure attacks in women are milder 101. 
Numerous researchers reported neuroprotec-
tive action of estrogen and progesterone102,103. 
These hormones influence not only seizure in-
tensity, but estrogen protects neurons from 
death by activation of bcl family genes or 
growth factors, and by inhibition of caspase-3, 
IL-1 and IL-6 activities104. Furthermore, data 
from experiments on an animal model of trau-
matic brain injury indicate that progesterone 
significantly reduces neuronal damage in CA1 
and CA2 and brain oedema105. 
 
Based on the above-presented facts, it can be 
assumed that the substances produced by the 
organism (neuropeptides, growth factors and 
even hormones) are more promising neuropro-
tectants for therapeutic prevention of genera-
tion and spread of epileptic stimulation in the 
brain than exogenous neuroprotective agents 
like FK506 or CsA. Researchers and clinicians 
need only to find a proper stimulation, assuring 
the adequate change in their level at critical 
time for seizure occurrence. 
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